• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    862.86 +18.36 (+2.17%)
    Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Chesapeake Sells 9,900 Eli Lilly (LLY) Shares Worth $7.7 Million
    Via The Motley Fool
    Topics Regulatory Compliance
    2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
    These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial. 
    Via The Motley Fool
    Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly?
    The smaller drugmaker is looking to disrupt a fast-growing market. 
    Via The Motley Fool
    Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
    Investors should be able to count on these stocks to deliver steady and growing income over the long term. 
    Via The Motley Fool
    Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials
    Via Stocktwits
    Smart Money Is Betting Big In LLY Options
     
    Via Benzinga
    Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
    Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments 
    Via MarketBeat
    Topics World Trade
    Chesapeake Asset Management Begins Investing in Ryder System. Is the Stock a Buy?
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
    Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes. 
    Via Benzinga
    Eli Lilly Stock: Elevated Momentum, Strong Analyst Backing, Near-Term Earnings Focus
    Eli Lilly's stock shows robust momentum and strong analyst support, driven by solid fundamentals and positive market sentiment, while upcoming earnings releases remain a focal point for investors. 
    Via Talk Markets
    Meet the 1.4% Yield Dividend Stock That Could Soar in 2026
    The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value. 
    Via The Motley Fool
    New to Investing? These Are 3 Solid Blue Chip Stocks You Can Build Your Portfolio Around
    Regardless of your investing knowledge or experience, you can't go wrong with these three behemoths in your portfolio. 
    Via The Motley Fool
    Topics Artificial Intelligence
    1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today
    Despite the company's run in recent years, it's not too late to buy. 
    Via The Motley Fool
    Independence Bank of Kentucky Buys Another $3.1 Million Eli Lilly (NYSE: LLY) Shares
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    3 Healthcare Companies Insiders Are Buying
    Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years. 
    Via MarketBeat
    Topics Initial Public Offering
    FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly
    The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
    Via Stocktwits
    Jim Cramer Declares Wall Street Divided: Three Distinct Markets Emerge
    Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts... 
    Via MarketMinute
    Topics Artificial Intelligence Economy
    Recent Filing Shows That Sen. John Boozman Bought Over $49K Worth of iShares 7-10 Year Treasury Bond ETF Stock
     
    Via Benzinga
    Topics ETFs
    Down 44%, Should You Buy the Dip on Viking Therapeutics?
    The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
    Via The Motley Fool
    Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs
     
    Via Benzinga
    This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
    Is it too late to get on the bandwagon? 
    Via The Motley Fool
    The Smartest Growth Stock to Buy With $100 Right Now
    This beaten-down drugmaker is well positioned to turn things around. 
    Via The Motley Fool
    Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
    Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
    Via The Motley Fool
    Topics ETFs Government World Trade
    Should You Buy Novo Nordisk Right Now?
    The fallen pharma giant could make a big comeback in 2026. 
    Via The Motley Fool
    Should Investors Buy Eli Lilly Stock?
    Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies. 
    Via The Motley Fool
    MarketBeat Week in Review – 10/06 - 10/10
    Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data 
    Via MarketBeat
    Topics Economy
    Why Hims & Hers Health (HIMS) Stock Is Nosediving
    Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue... 
    Via StockStory
    Topics World Trade
    Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations
    Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries. 
    Via Benzinga
    1 Vanguard ETF to Invest In That Can Turn $500 Monthly Into $800,000
    This ETF has shown market-beating potential since its inception. 
    Via The Motley Fool
    Topics ETFs
    2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now
    Ongoing developments make these companies look attractive. 
    Via The Motley Fool
    Topics Economy World Trade
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.